These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

390 related items for PubMed ID: 16169855

  • 21. Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells.
    Coudert JD, Zimmer J, Tomasello E, Cebecauer M, Colonna M, Vivier E, Held W.
    Blood; 2005 Sep 01; 106(5):1711-7. PubMed ID: 15886320
    [Abstract] [Full Text] [Related]

  • 22. Important roles for gamma interferon and NKG2D in gammadelta T-cell-induced demyelination in T-cell receptor beta-deficient mice infected with a coronavirus.
    Dandekar AA, O'Malley K, Perlman S.
    J Virol; 2005 Aug 01; 79(15):9388-96. PubMed ID: 16014902
    [Abstract] [Full Text] [Related]

  • 23. IL-21 enhances tumor rejection through a NKG2D-dependent mechanism.
    Takaki R, Hayakawa Y, Nelson A, Sivakumar PV, Hughes S, Smyth MJ, Lanier LL.
    J Immunol; 2005 Aug 15; 175(4):2167-73. PubMed ID: 16081783
    [Abstract] [Full Text] [Related]

  • 24. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
    Parihar R, Rivas C, Huynh M, Omer B, Lapteva N, Metelitsa LS, Gottschalk SM, Rooney CM.
    Cancer Immunol Res; 2019 Mar 15; 7(3):363-375. PubMed ID: 30651290
    [Abstract] [Full Text] [Related]

  • 25. NKG2D recognition and perforin effector function mediate effective cytokine immunotherapy of cancer.
    Smyth MJ, Swann J, Kelly JM, Cretney E, Yokoyama WM, Diefenbach A, Sayers TJ, Hayakawa Y.
    J Exp Med; 2004 Nov 15; 200(10):1325-35. PubMed ID: 15545356
    [Abstract] [Full Text] [Related]

  • 26. DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy.
    Töpfer K, Cartellieri M, Michen S, Wiedemuth R, Müller N, Lindemann D, Bachmann M, Füssel M, Schackert G, Temme A.
    J Immunol; 2015 Apr 01; 194(7):3201-12. PubMed ID: 25740942
    [Abstract] [Full Text] [Related]

  • 27. An activating immunoreceptor complex formed by NKG2D and DAP10.
    Wu J, Song Y, Bakker AB, Bauer S, Spies T, Lanier LL, Phillips JH.
    Science; 1999 Jul 30; 285(5428):730-2. PubMed ID: 10426994
    [Abstract] [Full Text] [Related]

  • 28. Comparative analysis of human NK cell activation induced by NKG2D and natural cytotoxicity receptors.
    André P, Castriconi R, Espéli M, Anfossi N, Juarez T, Hue S, Conway H, Romagné F, Dondero A, Nanni M, Caillat-Zucman S, Raulet DH, Bottino C, Vivier E, Moretta A, Paul P.
    Eur J Immunol; 2004 Apr 30; 34(4):961-71. PubMed ID: 15048706
    [Abstract] [Full Text] [Related]

  • 29. Engagement of NKG2D by cognate ligand or antibody alone is insufficient to mediate costimulation of human and mouse CD8+ T cells.
    Ehrlich LI, Ogasawara K, Hamerman JA, Takaki R, Zingoni A, Allison JP, Lanier LL.
    J Immunol; 2005 Feb 15; 174(4):1922-31. PubMed ID: 15699119
    [Abstract] [Full Text] [Related]

  • 30. A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity.
    Diefenbach A, Hsia JK, Hsiung MY, Raulet DH.
    Eur J Immunol; 2003 Feb 15; 33(2):381-91. PubMed ID: 12645935
    [Abstract] [Full Text] [Related]

  • 31. Sestrins induce natural killer function in senescent-like CD8+ T cells.
    Pereira BI, De Maeyer RPH, Covre LP, Nehar-Belaid D, Lanna A, Ward S, Marches R, Chambers ES, Gomes DCO, Riddell NE, Maini MK, Teixeira VH, Janes SM, Gilroy DW, Larbi A, Mabbott NA, Ucar D, Kuchel GA, Henson SM, Strid J, Lee JH, Banchereau J, Akbar AN.
    Nat Immunol; 2020 Jun 15; 21(6):684-694. PubMed ID: 32231301
    [Abstract] [Full Text] [Related]

  • 32. Human tumor-derived exosomes down-modulate NKG2D expression.
    Clayton A, Mitchell JP, Court J, Linnane S, Mason MD, Tabi Z.
    J Immunol; 2008 Jun 01; 180(11):7249-58. PubMed ID: 18490724
    [Abstract] [Full Text] [Related]

  • 33. UL16 binding proteins.
    Cao W, He W.
    Immunobiology; 2004 Jun 01; 209(3):283-90. PubMed ID: 15518340
    [Abstract] [Full Text] [Related]

  • 34. NKG2D-independent suppression of T cell proliferation by H60 and MICA.
    Kriegeskorte AK, Gebhardt FE, Porcellini S, Schiemann M, Stemberger C, Franz TJ, Huster KM, Carayannopoulos LN, Yokoyama WM, Colonna M, Siccardi AG, Bauer S, Busch DH.
    Proc Natl Acad Sci U S A; 2005 Aug 16; 102(33):11805-10. PubMed ID: 16091471
    [Abstract] [Full Text] [Related]

  • 35. IFN-dependent down-regulation of the NKG2D ligand H60 on tumors.
    Bui JD, Carayannopoulos LN, Lanier LL, Yokoyama WM, Schreiber RD.
    J Immunol; 2006 Jan 15; 176(2):905-13. PubMed ID: 16393975
    [Abstract] [Full Text] [Related]

  • 36. UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells.
    Sutherland CL, Chalupny NJ, Schooley K, VandenBos T, Kubin M, Cosman D.
    J Immunol; 2002 Jan 15; 168(2):671-9. PubMed ID: 11777960
    [Abstract] [Full Text] [Related]

  • 37. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity.
    Diefenbach A, Jensen ER, Jamieson AM, Raulet DH.
    Nature; 2001 Sep 13; 413(6852):165-71. PubMed ID: 11557981
    [Abstract] [Full Text] [Related]

  • 38. Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance.
    Oppenheim DE, Roberts SJ, Clarke SL, Filler R, Lewis JM, Tigelaar RE, Girardi M, Hayday AC.
    Nat Immunol; 2005 Sep 13; 6(9):928-37. PubMed ID: 16116470
    [Abstract] [Full Text] [Related]

  • 39. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages.
    Diefenbach A, Jamieson AM, Liu SD, Shastri N, Raulet DH.
    Nat Immunol; 2000 Aug 13; 1(2):119-26. PubMed ID: 11248803
    [Abstract] [Full Text] [Related]

  • 40. Ex vivo expansion of non-MHC-restricted cytotoxic effector cells as adoptive immunotherapy for myeloma.
    Wu JY, Ernstoff MS, Hill JM, Cole B, Meehan KR.
    Cytotherapy; 2006 Aug 13; 8(2):141-8. PubMed ID: 16698687
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.